Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NDRA vs NEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NEO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–3 Matrix Metrics)

NEO Overall Winner 6-Pillar Tally: NDRA 2 – 4 NEO Matrix Metrics: NDRA 3 – 5 NEO

As of Nov 17, 2026, NeoGenomics, Inc. (NEO) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas NEO carries 35.6/100 (SELL) at $15.49 (N/M Forward P/E, -5.5% operating margin).

  • Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. NEO 35.6/100 SELL), NEO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. 0.0% operating margin) and revenue trajectory (+11.4% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile NEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NDRA vs NEO
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32
NEO NASDAQ Head-to-Head Winner
NeoGenomics, Inc.
Services-Testing Laboratories
$15.49
+0.55% 1D
Market Cap $2.1B
TTM Revenue $788M
Forward P/E N/M
Beta / 30D Vol 1.23β · 47% Vol
Unified Composite Score
35.6 / 100 SELL
Tech 23.0 Fund 44.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 38
RSI-14: 37.8 · SMA20: $16.85 · SMA50: $17.51

6-Pillar Scorecard Institutional Category Breakdown (NDRA 2 – 4 NEO)

Columns: Metric · NDRA · NEO
1. Valuation Multiples NEO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M 2.09x
EV / Revenue N/M 3.0x
2. Growth & Scale NEO
Revenue Growth (YoY) +0.0% +11.4%
Earnings Growth (YoY) +0.0% +130.6%
TTM Revenue (USD) N/A $788M
Market Cap $6.6M $2.1B
3. Profitability & Quality NDRA
Gross Margin N/A 44.8%
Operating Margin 0.0% -5.5%
Net Profit Margin 0.0% -4.1%
Return on Equity (ROE) -152.0% -3.9%
4. Balance Sheet & Cash Flow NDRA
Cash Generation (TTM) -$8.0M -$29M
Cash Flow Margin N/A -3.6%
Net Cash / Leverage $104,744 Net Debt (0.26x D/E) $310M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NEO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 100.0% (14th %ile)
Put/Call OI Skew N/A 0.12x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NEO
OpEx & R&D Intensity N/A 50.3% of Rev ($396M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NDRA (3) vs NEO (5)
Institutional Metric NDRA NEO Criterion Row Edge
Market Capitalization
Scale
$6.6M $2.1B Larger Scale NEO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +11.4% Higher Growth NEO
Operating Margin (TTM)
Profitability
0.0% -5.5% Higher Margin NDRA
Net Profit Margin
Profitability
0.0% -4.1% Higher Margin NDRA
Return on Equity (ROE)
Capital Efficiency
-152.0% -3.9% Higher ROE NEO
52-Week Range Position
Momentum
37% ($3–$7) 64% ($7–$20) Stronger Trend NEO
Beta / 30D Volatility
Risk Regime
0.71β · 48% Vol 1.23β · 47% Vol Lower Realized Risk NEO
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 35.6 / 100 (SELL) Higher Composite NDRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $788M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.09x PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.0M ($104,744 Net Debt (0.26x D/E)) -$29M ($310M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NDRA +0.7 pp
NDRA: -6.75% · NEO: -7.45%
3M Horizon NDRA +1.08 pp
NDRA: -2.0% · NEO: -3.08%
6M Horizon NEO +102.41 pp
NDRA: -18.3% · NEO: +84.11%
1Y Horizon NEO +83.06 pp
NDRA: -34.03% · NEO: +49.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NDRA Revenue NEO Revenue NDRA Op. Margin NEO Op. Margin Margin Leader
FY2018 $0M $280M -146080.5% 3.6% NEO
FY2019 N/A $410M N/A 3.2% NEO
FY2020 N/A $440M N/A -3.1% NEO
FY2021 N/A $480M N/A -24.5% NEO
FY2022 N/A $510M N/A -30.9% NEO
FY2023 N/A $590M N/A -18.2% NEO
FY2024 N/A $660M N/A -13.9% NEO
FY2025 N/A $730M N/A -15.9% NEO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NEO CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 100.0%
IV Percentile 14th %ile
Put/Call OI Skew 0.12x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NEO Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.1B market capitalization and -5.5% operating margin.
OpEx & R&D Reinvestment 50.3% of Rev ($396M)
90D Engineering Disclosures 0 Published

Investor FAQ NDRA vs NEO Key Questions & Quantitative Answers

As of Nov 17, 2026, NeoGenomics, Inc. (NEO) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas NEO carries 35.6/100 (SELL) at $15.49 (N/M Forward P/E, -5.5% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. NEO 35.6/100 SELL), NEO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-5.5% vs. 0.0% operating margin) and revenue trajectory (+11.4% vs. +0.0% YoY). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile NEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NEO leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NEO at +11.4% YoY revenue growth and +130.6% YoY earnings growth on $788M TTM revenue (44.8% gross margin, -5.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NDRA cumulative revenue shifted N/A while NEO shifted +160.7%. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus 50.3% of Rev ($396M) (0 disclosures) for NEO.

NEO screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NEO trades at N/M Forward P/E, N/M Trailing P/E, 2.09x PEG, and 3.0x EV/Revenue (-3.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus NEO (-3.9% ROE) capital efficiency.

In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, NEO carries 100.0% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.23β · 47% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.